Article

Dr. George Addresses Provider Issues Regarding Immunotherapies

Conference|ASCO: American Society of Clinical Oncology

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer. He says that when the drug first came on the market many administrative challenges existed. There were limited access and associated reimbursement issues due to the limited production capabilities. However, Dr George states that currently there are no issues with payer coverage with little to no delays when it comes to prescribing the agent.

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Carrie Kitko
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Dr John Mascarenhas
CK Wang, MD, COTA
Dr Pankit Vachhani
Dr John Mascarenhas
Dr John Mascarenhas
Related Content
Alexander I. Spira, MD, PhD | Image: Virginia Cancer Specialists
July 3rd 2025

COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

Alexander I. Spira, MD, PhD Interview by Mary Caffrey
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic treatment reduces dermatological adverse events in patients with non–small cell lung cancer (NSCLC), enhancing their quality of life during amivantamab therapy.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Surgeons performing bariatric surgery on patient | Image credit: Vadim – stock.adobe.com
July 1st 2025

Surgeries and Endoscopic Procedures Offer Different Benefits for MASLD

Hayden E. Klein
Researchers said longitudinal studies are critical to refine and optimize the management of metabolic dysfunction–associated steatotic liver disease (MASLD).
managed care cast logo
November 27th 2024

Operationalizing Bispecifics in Multiple Myeloma

Mary Caffrey Laura Joszt, MA
Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.
Joshua K. Sabari, MD | Image: NYU Langone
Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey
Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Without IRA Fix, COA Warns Community Oncology Practices Will Shut Down
June 30th 2025

Without IRA Fix, COA Warns Community Oncology Practices Will Shut Down

Mary Caffrey
Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo